Clinical Scorecard: Reply to Editorial Correspondence on the Immunogenicity of Advanced Influenza Vaccines and Their Role in Neuraminidase Inhibition Antibody Production

At a Glance

Key Highlights

• NA content in influenza vaccines is not standardized and varies across formulations.
• NA protein content alone does not predict immunogenicity or NAI antibody response.
• High baseline antibody titers can reduce postvaccination antibody fold-rise due to an antibody ceiling effect.

Guideline-Based Recommendations

Diagnosis

• Assess baseline NAI and hemagglutination inhibition (HAI) antibody titers to interpret vaccine response.

Management

• Use multiple endpoints including seroconversion rates, geometric mean titers at baseline and postvaccination, and fold-rise to evaluate vaccine immunogenicity.

Monitoring & Follow-up

• Monitor NAI antibody titers pre- and postvaccination to assess immunogenicity in older adults.

Risks

• Potential misclassification of vaccine response in individuals with high baseline antibody titers.

Patient & Prescribing Data

Older adults receiving enhanced influenza vaccines including standard-dose, high-dose, recombinant, and adjuvanted formulations

Enhanced vaccines with higher NA content do not necessarily elicit higher NAI antibody responses; immunogenicity depends on multiple factors beyond NA quantity.

Clinical Best Practices

• Evaluate multiple immunological endpoints rather than relying solely on seroconversion rates to assess vaccine efficacy.
• Consider baseline antibody levels when interpreting postvaccination antibody responses.
• Recognize the current knowledge gaps in NA immunogenicity determinants and the need for standardized NA antigen quantification methods.
• Future research should focus on defining immunological correlates of protection related to anti-NA antibodies.

References

• Original study on NA antibody responses in older adults
• Studies on variable NA content in influenza vaccines
• Research on NA protein stability and immunogenicity
• Gao et al. on NA enzyme activity and immunogenicity
• Antibody ceiling effect in influenza vaccination